Bolt Biotherapeutics (NASDAQ:BOLT) Price Target Lowered to $5.00 at Morgan Stanley

Bolt Biotherapeutics (NASDAQ:BOLTGet Rating) had its price target decreased by Morgan Stanley to $5.00 in a research report issued on Tuesday, Stock Target Advisor reports. The brokerage currently has an “equal weight” rating on the stock. Morgan Stanley’s target price would indicate a potential upside of 214.47% from the stock’s previous close.

BOLT has been the topic of several other reports. Zacks Investment Research downgraded Bolt Biotherapeutics from a “buy” rating to a “hold” rating in a research note on Friday, April 29th. Stifel Nicolaus decreased their price objective on Bolt Biotherapeutics from $16.00 to $13.00 in a report on Friday. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Based on data from, the stock presently has a consensus rating of “Buy” and an average target price of $19.85.

Shares of BOLT stock traded up $0.04 on Tuesday, reaching $1.59. 4,054 shares of the company’s stock were exchanged, compared to its average volume of 346,093. Bolt Biotherapeutics has a 52 week low of $1.39 and a 52 week high of $20.49. The company has a current ratio of 10.16, a quick ratio of 10.16 and a debt-to-equity ratio of 0.09. The stock has a market capitalization of $59.58 million, a PE ratio of -0.60 and a beta of 2.06. The company’s fifty day simple moving average is $2.37 and its 200 day simple moving average is $4.45.

Bolt Biotherapeutics (NASDAQ:BOLTGet Rating) last released its quarterly earnings data on Wednesday, March 30th. The company reported ($0.73) EPS for the quarter, topping the consensus estimate of ($0.81) by $0.08. As a group, sell-side analysts predict that Bolt Biotherapeutics will post -2.97 earnings per share for the current fiscal year.

Large investors have recently bought and sold shares of the business. Point72 Hong Kong Ltd purchased a new stake in Bolt Biotherapeutics during the 3rd quarter worth approximately $26,000. Royal Bank of Canada increased its stake in Bolt Biotherapeutics by 206.9% during the 3rd quarter. Royal Bank of Canada now owns 2,437 shares of the company’s stock worth $31,000 after buying an additional 1,643 shares in the last quarter. Citigroup Inc. increased its stake in Bolt Biotherapeutics by 262.0% during the 3rd quarter. Citigroup Inc. now owns 2,842 shares of the company’s stock worth $36,000 after buying an additional 2,057 shares in the last quarter. Morgan Stanley purchased a new stake in Bolt Biotherapeutics during the 1st quarter worth approximately $156,000. Finally, Metropolitan Life Insurance Co NY purchased a new stake in shares of Bolt Biotherapeutics in the third quarter valued at approximately $91,000. Institutional investors own 89.78% of the company’s stock.

About Bolt Biotherapeutics (Get Rating)

Bolt Biotherapeutics, Inc, a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors; BDC-2034, a carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers; and BDC-3042, a Dectin-2 agonist antibody program developed to repolarize critical cells in the tumor microenvironment by targeting cell-surface receptors on macrophages.

Featured Stories

Stock Target Advisor logo

Receive News & Ratings for Bolt Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bolt Biotherapeutics and related companies with's FREE daily email newsletter.